1. Home
  2. VIGL vs ZBAO Comparison

VIGL vs ZBAO Comparison

Compare VIGL & ZBAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • ZBAO
  • Stock Information
  • Founded
  • VIGL 2020
  • ZBAO 2015
  • Country
  • VIGL United States
  • ZBAO China
  • Employees
  • VIGL N/A
  • ZBAO N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • ZBAO
  • Sector
  • VIGL Health Care
  • ZBAO
  • Exchange
  • VIGL Nasdaq
  • ZBAO NYSE
  • Market Cap
  • VIGL 95.2M
  • ZBAO 70.9M
  • IPO Year
  • VIGL 2022
  • ZBAO 2024
  • Fundamental
  • Price
  • VIGL $1.70
  • ZBAO $1.89
  • Analyst Decision
  • VIGL Buy
  • ZBAO
  • Analyst Count
  • VIGL 6
  • ZBAO 0
  • Target Price
  • VIGL $16.60
  • ZBAO N/A
  • AVG Volume (30 Days)
  • VIGL 375.1K
  • ZBAO 712.1K
  • Earning Date
  • VIGL 11-07-2024
  • ZBAO 02-03-2025
  • Dividend Yield
  • VIGL N/A
  • ZBAO N/A
  • EPS Growth
  • VIGL N/A
  • ZBAO N/A
  • EPS
  • VIGL N/A
  • ZBAO 0.06
  • Revenue
  • VIGL N/A
  • ZBAO $25,274,784.00
  • Revenue This Year
  • VIGL N/A
  • ZBAO $65.08
  • Revenue Next Year
  • VIGL N/A
  • ZBAO $34.27
  • P/E Ratio
  • VIGL N/A
  • ZBAO $29.31
  • Revenue Growth
  • VIGL N/A
  • ZBAO 29.25
  • 52 Week Low
  • VIGL $1.60
  • ZBAO $1.58
  • 52 Week High
  • VIGL $6.06
  • ZBAO $5.70
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 23.30
  • ZBAO N/A
  • Support Level
  • VIGL $1.60
  • ZBAO N/A
  • Resistance Level
  • VIGL $2.46
  • ZBAO N/A
  • Average True Range (ATR)
  • VIGL 0.16
  • ZBAO 0.00
  • MACD
  • VIGL -0.02
  • ZBAO 0.00
  • Stochastic Oscillator
  • VIGL 11.63
  • ZBAO 0.00

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About ZBAO ZHIBAO TECHNOLOGY INC

Zhibao Technology Inc is a insurance technology company engaged in providing digital insurance brokerage services in China. 2B2C digital embedded insurance is their business model which is pioneered in China. It provides customized digital insurance solutions for B-side channels (covering a wide range of industries and organizations, including but not limited to Internet platforms, large and medium-sized enterprises, and government agencies, etc.), embedding them into the channel's existing business matrix, and providing the channel with Provide digital insurance brokerage services to C-end customers.

Share on Social Networks: